首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

【2h】

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

机译：校正至：纳武单抗联合舒尼替尼或帕唑帕尼治疗晚期或转移性肾细胞癌的安全性和有效性：CheckMate 016研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Asim Amin; Elizabeth R. Plimack; Marc S. Ernstoff; Lionel D. Lewis; Todd M. Bauer; David F. McDermott; Michael Carducci; Christian Kollmannsberger; Brian I. Rini; Daniel Y. C. Heng; Jennifer Knox; Martin H. Voss; Jennifer Spratlin; Elmer Berghorn; Lingfeng Yang; Hans J. Hammers;
展开▼
作者单位

展开▼
年(卷),期 2019(7),-1
年度 2019
页码 73
总页数 1
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study [J] . Hammers Hans J., Plimack Elizabeth R., Infante Jeffrey R., Journal of Clinical Oncology . 2017,第34期

机译：Nivolumab与Ipilimalab在转移性肾细胞癌中的安全性和有效性：Checkmate 016研究
2. Early Completion of Phase-III-Study CheckMate-214: Nivolumab in Combination with Ipilimumab shows an Overall Survival Benefit in Patients with previously untreated advanced or metastatic Renal Cell Carcinoma [J] . Oncology research and treatment. . 2017,第11期

机译：早期完成期 - III研究的checkmate-214：Nivolumab与Ipilimumab的组合显示出先前未经处理的先进或转移性肾细胞癌患者的整体存活益处
3. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11) [J] . Retz Margitta, Bedke Jens, Boegemann Martin, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Switch II：III期随机，顺序，开放标签研究，以评估Sorafenib-Pazopanib对Pazopanib-Sorafenib的疗效和安全性在治疗晚期或转移性肾细胞癌（Auo 33/11）中的疗效和安全性
4. Integration of Surgery and Systemic Therapy in the Treatment of Locally Advanced and Metastatic Renal Cell Carcinoma [C] . Christopher G. Wood Genitourinary Cancers Symposium . 2011

机译：外科和全身治疗在局部晚期和转移性肾细胞癌中的整合
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study [O] . Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, 2018

机译：纳武单抗联合舒尼替尼或帕唑帕尼治疗晚期或转移性肾细胞癌的安全性和有效性：CheckMate 016研究
7. Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study [O] . Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, 2020

机译：Nivolumab在晚期非透明细胞肾细胞癌患者中的安全性和有效性：IIIB阶段/ IV检查的结果374研究

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

著录项

相似文献

相关主题

期刊订阅